The med-tech financial landscape is continuing an upturn after investments languished following the 2008 recession. While other health care sectors recovered sooner, companies that produce medical technologies resurged last year with a growing interest from investors in digital technologies that fit well with an outcome-based reimbursement model. Financings tracked by BioWorld MedTech indicate that 2018 is holding steady with the prior year. Public markets are outperforming other health care sectors, and series A investing is at a decade high.